Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 5/20 | 0.37 |
| ▸ | ALPI | P09923 | 5/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8300933 | 0.87 | CNR1 (0.40) | CNR1CNR2MEN1GPR183KMT2A | |
| SCHEMBL7228892 | 0.87 | CNR1 (0.41) | CNR1CNR2MEN1GPR183KMT2A | |
| Hydrochloric Acid SCHEMBL7221177 | 0.86 | CNR1 (0.39) | CNR1CNR2MEN1GPR183KMT2A | |
| SCHEMBL7228982 | 0.83 | CNR1 (0.44) | CNR1CNR2MEN1GPR183KMT2A | |
| SCHEMBL7227793 | 0.71 | MRGPRX1 (0.45) | CNR1CNR2MEN1KMT2AALPL | |
| SCHEMBL27692886 | 0.69 | ALPL (0.45) | CNR1CNR2MEN1KMT2AALPL | |
| SCHEMBL6706440 | 0.69 | CNR1 (0.41) | CNR1CNR2MEN1GPR183KMT2A | |
| SCHEMBL7220492 | 0.68 | CNR2 (0.64) | CNR1CNR2MEN1GPR183KMT2A | |
| SCHEMBL2362375 | 0.68 | HTR1B (0.47) | CNR1CNR2ALPLALPI | |
| SCHEMBL4481326 | 0.67 | HTR1B (0.46) | CNR1CNR2ALPLALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| EP-0966436-B1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| EP-0966436-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Bayer Aktiengesellschaft (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998037061-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | CNR1 190/4885CNR2 224/4885MEN1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.